Project Grant R01HL187555
Award Date 9/1/26
Completion Date 5/31/30
Dollars Obligated $688K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Gainesville, FL 32611, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Wake Forest University Health Sciences $765,811 on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate fatty acid oxidation and myosteatosis in peripheral artery disease. The research project examines the role of fatty acid oxidation in limb tissue mitochondria as a cause of myosteatosis and chronic limb-threatening ischemia presentations, and explores it as a site for interventional therapies. The...
- The National Heart, Lung, and Blood Institute awarded Research Institute At Nationwide Children's Hospital $1,326,945 on September 10, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a translatable molecular imaging paradigm for comprehensive assessment of peripheral artery disease (PAD). The recipient will characterize stages of peripheral atherosclerosis using dual-phase PET/CT imaging with fluorine-18 sodium fluoride (18F-NAF) to quantify both regional muscle...
- The National Heart, Lung, and Blood Institute awarded the University of Florida Division of Sponsored Research $228,750 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to characterize pain phenotypes in patients with chronic limb-threatening ischemia, the most advanced form of peripheral arterial disease. The project will systematically document pain features, severity, and mechanisms in lower-extremity CLTI patients to inform precision pain management and...
- The National Heart, Lung, and Blood Institute awarded New York University $872,787 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct proteomic discovery and validation research on chronic limb-threatening ischemia (CLTI), the most severe form of peripheral artery disease. The award funds development of proteomic signatures to predict major adverse limb events (MALE) and major adverse cardiovascular events (MACE) in CLTI patients, and to guide...
- The National Heart, Lung, and Blood Institute awarded the University of Miami $345,375 on April 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of gasdermin-D in neonatal hyperoxia-induced vascular remodeling and cardiac dysfunction. The project grant (R03HL183267) runs through February 28, 2028, with work performed in Miami, Florida. The research targets mechanisms by which oxygen therapy in preterm infants—necessary to ensure adequate oxygen...
- The National Heart, Lung, and Blood Institute awarded $765,131 to the Regents of the University of Minnesota on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on mechanisms mediating an exaggerated exercise pressor reflex in a murine model of hindlimb ischemia and peripheral artery disease. The research uses novel mouse models to investigate why patients with peripheral artery disease display abnormal cardiovascular responses during...
- The National Institutes of Health National Heart Lung and Blood Institute awarded The Medical University of South Carolina $188,568 under the Cardiovascular Diseases Research program (CFDA 93.837) on April 1, 2026, to investigate skeletal muscle microvascular dysfunction in systolic heart failure. The award funds research comparing pre- and post-exercise assessments of noninvasive measures of skeletal muscle microvascular function in the distal leg alongside invasive hemodynamic monitoring to...
- The National Heart, Lung, and Blood Institute awarded the University of Florida $249,000 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research into how genetic factors, specifically apolipoprotein E4 (APOE4) alleles and inflammation, influence respiratory plasticity mechanisms. The research builds on prior K99 phase work and investigates phrenic long-term facilitation (PLTF), a prolonged increase in phrenic motor output triggered by moderate...
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $554,085 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the interconnection between actin dynamics and cardiac metabolic homeostasis, specifically examining how defects in mitochondrial clearance contribute to heart failure and neuromuscular diseases including Parkinson's disease. The research explores the spatiotemporal regulation of...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $776,745 on August 17, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and target DELE1-mediated mitochondrial stress signaling in cardiomyopathy. The research addresses how mitochondrial dysfunction drives cardiovascular disease, including heart failure and ischemic injury, by characterizing the molecular mechanisms through which DELE1 acts as a mitochondrial stress sensor to...